Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can exercise boost a Weight-Loss drug? new study aims to find out

NCT ID NCT07298915

Disease control Sponsor: University of Virginia Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether adding exercise to the weight-loss medication tirzepatide helps people lose more weight and improve health markers like blood sugar and cholesterol. Researchers will enroll 24 adults aged 30–65 with overweight or obesity. Participants will take tirzepatide for 16 weeks, and some will also do supervised aerobic and resistance training three times a week.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
tirzepatide and exercise
What this could lead to
If it works, this could show that combining exercise with weight-loss medication leads to greater fat loss and better heart health than medication alone.
What could go wrong
This is a small, early-phase trial with only 24 people, so results may not apply to everyone. Exercise adherence can be low, and tirzepatide may cause side effects like nausea.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 24 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Men and women 30-65 years of age, postmenopausal women included * 27-29.9 with an additional CVD risk factor or 30-40 kg/m2 * For overweight adults only: additional cardiometabolic risk factor (diagnosed dyslipidemia, hypertension) * Willingness and adequate health to go on weight loss medication * The capability and willingness to provide written informed consent * Approval of their primary care provider to go on weight loss medication Exclusion Criteria: * Including but not limited to serious arrhythmias * Cardiomyopathy * Congestive heart failure * Stroke or transient ischemic attacks * Peripheral vascular disease * Previous history of myocardial infarction or stroke * Previous diagnosis or taking medication for type 1 or 2 diabetes, fasting glucose \>125 mg/dL or HbA1C ≥6.5% * Systolic blood pressure \>160 mmHg and diastolic blood pressure \>100 mmHg. * Hospitalization for mental illness within the past 5 years or currently undergoing treatment for severe mental illness * Conditions that can be aggravated or are contraindicated by exercise training * Plans to be out of town more than 3 weeks in the next 4 months. * Currently pregnant or plans to become pregnant * Currently in a diet or exercise program * Non-compliance during screening or extreme difficulty in obtaining baseline blood samples * Enrolled in a different exercise program * Previous weight loss surgery * Use of weight loss medication within the last year * hypo/hyper thyroid (medicated or unmedicated)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity & overweight are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Motor Activity Obesity obesity disorder Overweight Weight Loss

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity & overweight

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Virginia

    Charlottesville, Virginia, 22901, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.